Health Professional Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Professional Times.

Press releases published on April 17, 2026

Apr. 17, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Apr. 17, 2026

Keeps Hair Growth Product Claims Evaluated: Topical & Oral RX Hair Loss Prescription Treatment with Finasteride, Dutasteride & Minoxidil

Indeterminate GlobeNewswire

Apr. 17, 2026

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Indeterminate GlobeNewswire

Apr. 17, 2026

Global mRNA Targeting Biopolymers Market Witnesses Robust Growth as Europe Emerges Strong with BioNTech, CureVac & Roche

Indeterminate EIN Presswire

Apr. 17, 2026

Professional 3D Dental Scans Now Available at ALIGNERCO’s Dallas-Fort Worth Partner Clinics

Indeterminate EIN Presswire

Apr. 17, 2026

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Apr. 17, 2026

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Indeterminate GlobeNewswire

Apr. 17, 2026

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

4DMT Announces New Employment Inducement Grants

Indeterminate GlobeNewswire

Apr. 17, 2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Apr. 17, 2026

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Indeterminate GlobeNewswire

Apr. 17, 2026

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Indeterminate GlobeNewswire

Apr. 17, 2026

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Indeterminate GlobeNewswire

Apr. 17, 2026

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

Medical AI Society Announces Inaugural Governance Symposium in Dublin

Indeterminate EIN Presswire

Apr. 17, 2026

SplashBI Recognized as a Star Performer in Everest Group’s People Analytics Platforms PEAK Matrix® Assessment 2026

Indeterminate EIN Presswire